Sign inJoin waitlistJoin the waitlist

Gregory Masters

Faculty · Christiana Care Health Services Inc

Credentials: · · · ·

History

Christiana Care Health Services Inc
Present

University of Chicago Medical Center
1993–1995
Internal Medicine
1990–1993
Feinberg School of Medicine
1986–1990

Research

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB…
The Lancet Oncology · 2015 · 1,643 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer · 2021 · 762 citations
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Science Immunology · 2016 · 676 citations

Everett Vokes
30 papers
Philip Hoffman
18 papers
HG
Harvey Golomb
17 papers
JS
Joan Schiller
13 papers
Bryan Schneider
12 papers
David Johnson
12 papers
Ishmael Jaiyesimi
11 papers
Julie Brahmer
11 papers
JB
Jeffrey Bogart
10 papers
LD
Lee Drinkard
10 papers · 2 as a fellow
Nasser Hanna
10 papers
SB
Sherman Baker
10 papers

Grants

Delaware Christiana Care NCORP
National Cancer Institute · UG1
Contact PI · $21.6M · Christiana Care Health Services, Inc.
2014–2027

Clinical trials

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Study chair · Completed · Phase 3
Radiation Therapy Oncology Group
2007–2022
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Study chair · Completed · Phase 2
Eastern Cooperative Oncology Group
2002–2007
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2027–2032
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029